<![CDATA[Abstract: Statins, lipid-lowering drugs, are used to reduce low density lipoprotein cholesterol (LDL-C). Although statins are well tolerated by most people, their side effects e. g. myopathy and statin intolerance have impacts on dose reduction and therapy discontinuation. Evolocumab is considered in patients with statin intolerance. This study aimed to determine the effect of evolocumab on LDL-C levels in patients with dyslipidemia and statin intolerance. This was a literature review study using literature search on three databases, namely PubMed, ClinicalKey, and ScienceDirect with the keywords Dyslipidemia AND Evolocumab AND Statin Intolerance. The results obtained seven related literatures. In general, evolocumab therapy was safe and effective in reducing LDL-C levels for patients who needed drugs to lower LDL-C. Based on the literatures, inhibition of PCSK9 activity on evolocumab had an effect on reducing LDL-C levels by 50-70%. This therapy could reduce the risk of cardiovascular diseases such as the ratio of Apo B/Apo A1, triglycerides, and total cholesterol. In conclusion, evolocumab therapy is generally safe and effective in significantly reducing LDL-C. Adverse effects caused by the therapy tend to be mild. Keywords: dyslipidemia; low density lipoprotein cholesterol; statins; statin intolerance; evolocumab Abstrak: Statin merupakan obat penurun lipid untuk menurunkan kolesterol low density lipoprotein (K-LDL) dan umumnya dapat ditoleransi dengan baik namun miopati dan efek samping lainnya serta intoleransi statin dapat mengarah ke penurunan dosis atau penghentian terapi. Pemberian evolocumab dapat dipertimbangkan pada keadaan intoleransi statin. Penelitian ini bertujuan untuk mengetahui pengaruh evolocumab terhadap kadar K-LDL pasien dengan dislipidemia dan intoleransi statin melalui suatu literature review. Pencarian literatur pada tiga database, yaitu PubMed, ClinicalKey, dan ScienceDirect dengan kata kunci Dyslipidemia AND Evolocumab AND Statin Intolerance. Hasil penelitian mendapatkan tujuh literatur untuk dikaji. Berdasarkan kajian literatur didapatkan terapi evolocumab umumnya aman dan efektif dalam menurunkan kadar K-LDL bagi pasien yang membutuhkan obat untuk penurunan kolesterol. yang telah didapat. Penghambatan aktivitas PCSK9 pada evolocumab berpengaruh dalam menurunkan kadar K-LDL sekitar 50-70%. Terapi tersebut dapat mengurangi risiko penyakit kardiovaskular seperti rasio Apo B/Apo A1, trigliserida, dan kolesterol total. Simpulan penelitian ini ialah terapi evolocumab umumnya aman dan efektif dalam menurunkan kadar K-LDL secara bermakna. Kejadian yang tidak diinginkan yang ditimbulkan oleh terapi cenderung ringan. Kata kunci: dislipidemia; kolesterol low density lipoprotein; statin; intoleransi statin; evolocumab]]>
Copyrights © 2024
